A dramatic change in HIV treatment.
Department of Dermatology, University of California-San Francisco, USA.
Karl
K
Wilkins
Toby
T
Maurer
Timothy
T
Berger
D017088:AIDS-Related Opportunistic Infections / Q000209:etiology; D044966:Anti-Retroviral Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000209:etiology; D002294:Carcinoma, Squamous Cell / Q000209:etiology; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006566:Herpesviridae Infections / Q000209:etiology; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000209:etiology; D008545:Melanoma / Q000209:etiology; D012514:Sarcoma, Kaposi / Q000209:etiology; D012878:Skin Neoplasms / Q000209:etiology; D016896:Treatment Outcome
D044966:Anti-Retroviral Agents